A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Clinical trial NCT06868277 · RECRUITING

Trial details

NCT number: NCT06868277
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Carcinoma, Non-Small Cell Lung

Start date: 2025-04-10
Primary completion: 2030-01-17
Enrollment: 830

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.